08:26 AM EDT, 05/29/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.

The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.

Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.

Shares of the company were down by more than 20% in recent Thursday premarket activity.